Changeflow GovPing Pharma & Drug Safety Mitochondria-targeted atovagone compounds and m...
Routine Notice Added Final

Mitochondria-targeted atovagone compounds and methods for antitumor, antimicrobial, and antimalarial treatment

Favicon for changeflow.com ChangeBridge: Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO granted Patent US12594283B2 to The Medical College of Wisconsin, Inc. covering mitochondria-targeted Atovaquone compounds (Mito-ATO) and methods of using such compounds for antitumor, antimicrobial, and antimalarial treatment. The patent contains 22 claims and was filed on October 26, 2020.

What changed

USPTO issued Patent US12594283B2 for novel mitochondria-targeted Atovaquone derivatives invented by Balaraman Kalyanaraman, Gang Cheng, and Micael Joël Hardy. The patent covers methods of treating cancer, enhancing anti-tumor immune responses, and antimicrobial/antimalarial applications using Mito-ATO compounds.

The patent grant establishes legally enforceable intellectual property rights for the Medical College of Wisconsin, preventing unauthorized manufacture, use, or sale of the claimed compounds and methods. Competitors in the pharmaceutical space should monitor this IP landscape when developing related therapeutic programs.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Mitochondria-targeted atovagone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug

Grant US12594283B2 Kind: B2 Apr 07, 2026

Assignee

The Medical College of Wisconsin, Inc.

Inventors

Balaraman Kalyanaraman, Gang Cheng, Micael Joël Hardy

Abstract

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

CPC Classifications

A61K 31/66 A61K 31/122 A61K 45/06 A61K 31/662 A61P 35/00 C07C 49/84 C07F 9/535 C07F 9/5435 C07F 9/5456

Filing Date

2020-10-26

Application No.

17770924

Claims

22

View original document →

Get daily alerts for ChangeBridge: Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594283B2

Who this affects

Applies to
Drug manufacturers Healthcare providers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing Drug development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Medical Devices

Get alerts for this source

We'll email you when ChangeBridge: Patent Grants - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.